BACKGROUND Low grade serous carcinoma of the ovary(LGSOC)is a rare type of epithelial ovarian cancer with a low incidence rate.The origin of ovarian cancer has always been a hot topic in gynecological oncology researc...BACKGROUND Low grade serous carcinoma of the ovary(LGSOC)is a rare type of epithelial ovarian cancer with a low incidence rate.The origin of ovarian cancer has always been a hot topic in gynecological oncology research,and some scholars believe that the origin of ovarian malignant tumors is the fallopian tubes.Primary fallopian tube cancer is the lowest incidence of malignant tumors in the female reproductive system.There are only a few reports in the literature,but the mortality rate is very high.But in clinical practice,fallopian tube cancer is very common,but in most cases,it is classified as ovarian cancer.CASE SUMMARY We report a 54 years old postmenopausal woman who was hospitalized with a lower abdominal mass and underwent surgical treatment.The final pathological confirmation was low-grade serous carcinoma of the right ovary and low-grade serous carcinoma of the left fallopian tube.No special treatment was performed after the surgery,and the patient was instructed to undergo regular follow-up without any signs of disease progression.CONCLUSION The prognosis of LGSOC is relatively good,over 80%of patients still experience disease recurrence.展开更多
Objective： The aim of this study was to compare the efficacies and safeties of the combination of docetaxel- carboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epith...Objective： The aim of this study was to compare the efficacies and safeties of the combination of docetaxel- carboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian, pri- mary peritoneal or fallopian tube cancers. Methods： Relevant articles were identified from MEDLINE （1993-2010）, EMBASE （1980-2010）, MEDION, the Cochrane library, Science Citation Index Expanded databases, hand searching of reference lists from primary articles and reviews, conference abstracts and contact with experts in the field. The review included 5 relevant primary studies （1430 women）. Data was extracted for study characteristics and quality. Bivariate random-effect model meta- analysis was used to estimate diagnostic accuracy of the various index tests. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies. Results： The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxel- carboplatin group （OR = 1.33, 95% CI = 1.13-1.56, P = 0.0005）, whereas that of clinical responses was equivalent in com- parison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin （OR = 1.0, 95% CI = 0.87-1.16, P = 0.95）. There were heterogeneity （X2 = 79.36, P 〈 0.00001） and inconsistency （83.6%） in toxicity analysis among the trials, while neither heterogeneity （x2 = 3.21, P = 0.99） nor inconsistency （F = 0%） in clinical responses among the trials. Conclusion： The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxel- carboplatin or docetaxel-cisplatin. However, the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.展开更多
From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate o...From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate of 40 %. The average length of remission was 5 months in CR and 3.9 months in PR. The major toxic side effect was decrease in total white cell count and in neutrophil count. Apart from flushing of face during Taxol infusion in 6 patients, no other allergic reaction was observed. Gastrointestinal, neurologic, liver and renal toxicities were mild. Taxol is a drug of choice in the treatment of patients with cancer of the ovary and Fallopian tube who are resistant to conventional chemotherapy.展开更多
目的研究Wnt抑制因子(dickkopf-related protein 3,DKK3)在原发性输卵管癌中的表达,并探讨DKK3启动子甲基化的临床意义。方法选取46例输卵管癌患者的输卵管癌组织标本和相应的癌旁组织标本。通过免疫组织化学法检测DKK3蛋白表达情况,通...目的研究Wnt抑制因子(dickkopf-related protein 3,DKK3)在原发性输卵管癌中的表达,并探讨DKK3启动子甲基化的临床意义。方法选取46例输卵管癌患者的输卵管癌组织标本和相应的癌旁组织标本。通过免疫组织化学法检测DKK3蛋白表达情况,通过荧光定量PCR检测DKK3 mRNA的表达水平,通过甲基化特异性PCR(MSP)检测DKK3基因启动子甲基化水平,并分析其与患者临床病理的关系。结果免疫组化检测结果显示,输卵管癌组织中DKK3蛋白高表达率为28.3%(13/46),明显低于癌旁对照组65.2%(30/46),差异具有统计学意义(P<0.01)。荧光定量PCR结果显示,输卵管癌组织中DKK3 mRNA水平明显低于癌旁对照组,差异具有统计学意义(P<0.01)。MSP检测结果显示,输卵管癌组织DKK3基因发生甲基化概率为73.9%(34/46),明显高于癌旁对照组的39.1%(18/46),差异具有统计学意义(P<0.01)。DKK3启动子甲基化水平与输卵管癌患者年龄(χ^2=0.031,P>0.05)、输卵管癌病理分级(χ^2=3.184,P>0.05)和病理类型(χ^2=0.654,P>0.05)均无显著相关性。DKK3甲基化水平与FIGO分期存在显著相关性(χ^2=5.007,P<0.05)。结论DKK3基因启动子甲基化水平与输卵管癌的发生发展密切相关,可作为输卵管癌诊断和治疗的签字靶点。展开更多
文摘BACKGROUND Low grade serous carcinoma of the ovary(LGSOC)is a rare type of epithelial ovarian cancer with a low incidence rate.The origin of ovarian cancer has always been a hot topic in gynecological oncology research,and some scholars believe that the origin of ovarian malignant tumors is the fallopian tubes.Primary fallopian tube cancer is the lowest incidence of malignant tumors in the female reproductive system.There are only a few reports in the literature,but the mortality rate is very high.But in clinical practice,fallopian tube cancer is very common,but in most cases,it is classified as ovarian cancer.CASE SUMMARY We report a 54 years old postmenopausal woman who was hospitalized with a lower abdominal mass and underwent surgical treatment.The final pathological confirmation was low-grade serous carcinoma of the right ovary and low-grade serous carcinoma of the left fallopian tube.No special treatment was performed after the surgery,and the patient was instructed to undergo regular follow-up without any signs of disease progression.CONCLUSION The prognosis of LGSOC is relatively good,over 80%of patients still experience disease recurrence.
文摘Objective： The aim of this study was to compare the efficacies and safeties of the combination of docetaxel- carboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian, pri- mary peritoneal or fallopian tube cancers. Methods： Relevant articles were identified from MEDLINE （1993-2010）, EMBASE （1980-2010）, MEDION, the Cochrane library, Science Citation Index Expanded databases, hand searching of reference lists from primary articles and reviews, conference abstracts and contact with experts in the field. The review included 5 relevant primary studies （1430 women）. Data was extracted for study characteristics and quality. Bivariate random-effect model meta- analysis was used to estimate diagnostic accuracy of the various index tests. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies. Results： The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxel- carboplatin group （OR = 1.33, 95% CI = 1.13-1.56, P = 0.0005）, whereas that of clinical responses was equivalent in com- parison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin （OR = 1.0, 95% CI = 0.87-1.16, P = 0.95）. There were heterogeneity （X2 = 79.36, P 〈 0.00001） and inconsistency （83.6%） in toxicity analysis among the trials, while neither heterogeneity （x2 = 3.21, P = 0.99） nor inconsistency （F = 0%） in clinical responses among the trials. Conclusion： The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxel- carboplatin or docetaxel-cisplatin. However, the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.
文摘From September 1993 through March 1994, 30 cases of refractory carcinoma of the ovary and Fallopian tube were treated with Taxol. Complete response was seen in 4 and partial response in 8 cases with a response rate of 40 %. The average length of remission was 5 months in CR and 3.9 months in PR. The major toxic side effect was decrease in total white cell count and in neutrophil count. Apart from flushing of face during Taxol infusion in 6 patients, no other allergic reaction was observed. Gastrointestinal, neurologic, liver and renal toxicities were mild. Taxol is a drug of choice in the treatment of patients with cancer of the ovary and Fallopian tube who are resistant to conventional chemotherapy.
文摘目的研究Wnt抑制因子(dickkopf-related protein 3,DKK3)在原发性输卵管癌中的表达,并探讨DKK3启动子甲基化的临床意义。方法选取46例输卵管癌患者的输卵管癌组织标本和相应的癌旁组织标本。通过免疫组织化学法检测DKK3蛋白表达情况,通过荧光定量PCR检测DKK3 mRNA的表达水平,通过甲基化特异性PCR(MSP)检测DKK3基因启动子甲基化水平,并分析其与患者临床病理的关系。结果免疫组化检测结果显示,输卵管癌组织中DKK3蛋白高表达率为28.3%(13/46),明显低于癌旁对照组65.2%(30/46),差异具有统计学意义(P<0.01)。荧光定量PCR结果显示,输卵管癌组织中DKK3 mRNA水平明显低于癌旁对照组,差异具有统计学意义(P<0.01)。MSP检测结果显示,输卵管癌组织DKK3基因发生甲基化概率为73.9%(34/46),明显高于癌旁对照组的39.1%(18/46),差异具有统计学意义(P<0.01)。DKK3启动子甲基化水平与输卵管癌患者年龄(χ^2=0.031,P>0.05)、输卵管癌病理分级(χ^2=3.184,P>0.05)和病理类型(χ^2=0.654,P>0.05)均无显著相关性。DKK3甲基化水平与FIGO分期存在显著相关性(χ^2=5.007,P<0.05)。结论DKK3基因启动子甲基化水平与输卵管癌的发生发展密切相关,可作为输卵管癌诊断和治疗的签字靶点。
